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Abstract
Background: There have been few studies examining the associations between menstrual irregularity, androgens
and bone mass in population-based samples of premenopausal women. This study aimed to describe the
associations between menstrual pattern, testosterone, sex hormone binding globulin (SHBG) and bone mass in a
population-based sample of premenopausal women.
Methods: Cross-sectional study (N = 382, mean age 31.5 years). Menstrual pattern was assessed by questionnaire,
bone mass measured by quantitative ultrasound (QUS) and androgen status was assessed by levels of serum
testosterone, SHBG and the free androgen index (FAI).
Results: Women with irregular cycles (n = 41, 11%) had higher free androgen index (FAI, P = 0.01) and higher QUS
measurements including speed of sound (SOS, 1%, P < 0.05), quantitative ultrasound index (QUI, 7%, p < 0.05), and
broadband ultrasound attenuation (BUA, 7%, p = 0.10). These associations persisted after adjustment for age and
body mass index (BMI). After further adjustment for hormonal factors (either testosterone, SHBG or FAI), the
strength of the associations was moderately attenuated, however, women with irregular cycles still had a 6%
increase in mean QUS. Total testosterone, FAI and SHBG were also associated with QUS measures (testosterone
and FAI, r +0.11 to +0.21, all p < 0.05; SHBG r -0.14 to -0.16, all p < 0.05) and the associations remained significant
after adjustment.
Conclusion: Irregular menstrual cycles were associated with higher bone mass in this population-based sample of
premenopausal women suggesting menstrual disturbance should continue to be evaluated but may be less
harmful for bone mass. The association between menstrual irregularity and bone mass was partially mediated by
markers of androgen status especially free testosterone.
Background
Osteoporosis is a major public health concern [1]. Most
osteoporosis sufferers are postmenopausal women and
age-related estrogen deficiency is considered a major
cause of bone loss [2]. As well as estrogen, androgens
may also have an effect on bone metabolism in women;
excess levels of androgen are associated with higher
bone mass in women with Polycystic Ovary Syndrome
(PCOS) [3-7]. Menstrual irregularity has been associated
with lower bone mass in studies of female athletes who
had low BMI and extensive training [8-11]. However
these results may not directly apply to today’sp o p u l a -
tion of young women with a higher prevalence of over-
weight and obesity. Recent studies have suggested that
menstrual irregularity is associated with higher levels of
androgens in a population-based sample of premeno-
pausal women [12,13], while in female elite athletes oli-
gomenorrhea was associated with higher bone mass and
PCOS [14]. These results may in turn suggest a positive
association between menstrual irregularity and bone
mass. However, few studies have examined the associa-
tions between menstrual irregularity, androgen and bone
mass in population-based sample. Therefore, the aim of
this cross-sectional study was to describe the association
between menstrual pattern, testosterone, sex hormone
binding globulin (SHBG) and bone mass measured by
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sample of young women.
Methods
Subjects
This study utilized data from the Childhood Determi-
nants of Adult Health (CDAH) study, a 20-year follow-
up of children who were randomly selected for the 1985
Australian Schools Health andF i t n e s sS u r v e y( A S H F S )
at age 7-15 years. Details of the 1985 sampling strategy
have been described elsewhere [15]. During follow-up
(2004-2006) a total of 2410 subjects aged 26-36 years
(48% male, 52% female), completed questionnaires and
attended one of 34 study clinics in major cities and
regional centres around Australia for extensive physical
measurements including anthropometric measures,
quantitative ultrasound and blood biochemistry.
Eligible subjects for this study were women who had
completed study questionnaires, attended study clinics,
were not currently taking oral contraceptives, and not
pregnant or breast feeding at the time of clinic atten-
dance. Of the 1260 women who attended clinics, 82
were currently pregnant; 453 were currently taking hor-
monal contraceptives (including combined and progestin
only contraceptives and progestin releasing intrauterine
devices) or medications such as hormonal agents for
PCOS or in vitro fertilization (IVF); 44 did not provide
their menstrual cycle characteristics; and 299 had miss-
ing QUS measurements due to the machine being out
of service, leaving a total of 382 participants for this
analysis. All participants provided written informed con-
sent and the study was approved by the Southern Tas-
mania Health and Medical Human Research Ethics
Committee.
Assessment of menstrual cycle characteristics
Menstrual cycle characteristics were obtained by written
questionnaire. We defined the menstrual cycle as the
time from the first day of one period to the first day of
the next. The question was then asked: “ thinking about
the most recent time when you were having periods and
were not using hormonal contraceptives (e.g., the pill)
and were not pregnant or breast feeding: would you
describe your period as very regular, fairly regular, irre-
gular or very irregular [16]. To simplify analyses, men-
strual cycle pattern was defined as regular if women
described their periods as very or fairly regular, and irre-
gular if irregular or very irregular.
Hormone measurements
Blood samples (32 ml) were collected from participants
after an overnight fast. Plasma insulin was initially mea-
sured by a microparticle enzyme immunoassay kit
(AxSYM; Abbot Laboratories, Abbot Park, IL) and later,
following a change in the choice of kit by the testing
laboratory, by electrochemiluminescence immunoassay
(Elecsys Modular Analytics E170; Roche Diagnostics,
Mannheim, Switzerland). Due to this change in assay
methodology, insulin levels from participants’ samples
(N = 258) assayed using the first methodology were cor-
rected to levels in samples assayed using the second
methodology (as per correction factor equation of the
laboratory). Total testosterone concentrations were esti-
mated by radioimmunoassay (RIA) developed by
Repromed Laboratory (Dulwich, South Australia), which
is sensitive for lower levels of testosterone down to 347
pmol/L. SHBG was measured using a non-competitive
liquid-phase immunoradiometric assay (SHBG-IRMA
kit, Orion Diagnostica, Espoo, Finland). For testosterone,
the intra- and inter- assay coefficients of variation (CV)
were 6% at 1 nmol/l and 15%, respectively. For SHBG,
the intra- and inter- assay CV were 15.4%, and 2.0-8.6%
respectively. FAI was calculated as: testosterone
(nmol/L) * 100/SHBG (nmol/L).
Anthropometric measurements
Anthropometric measures were taken at study clinics by
trained personnel. Height and weight were measured to
the nearest 0.1 cm and 0.1 kg, respectively, and body
mass index (BMI) was calculated as the ratio of weight
(kg) to height (m) squared (kg/m
2). Waist to hip ratio
(WHR) was calculated by dividing waist by hip circum-
ference measured to the nearest 0.1 cm.
Quantitative ultrasound measurements
All participants had calcaneal QUS measured by a single
Sahara Clinical Bone Sonometer (Hologic Inc., MA,
USA). The ultrasound system consists of two sound
transducers mounted coaxially on a motorized calliper
with one transducer acts as an emitter and the other as
a receiver. This makes direct contact with the heel
through elastomer pads and an ultrasonic coupling gel.
The lower part of the dominant leg was placed immobi-
lized during measurement and the proper leg angle set
by a positioning aid. Broadband ultrasound attenuation
(BUA, dB/MHz) and speed of sound (SOS, m/s) were
measured at a fixed region in the mid-calcaneus. The
quantitative ultrasound index (QUI) was derived from
SOS and BUA using the equation: QUI = 0.41× (BUA
+SOS)-571 [17]. Quality assurance was performed daily
by calibrating the device on a dedicated phantom sup-
plied by the manufacturer. The coefficient of variation
(CV) for QUS measures was 1%.
Assessment of other covariates
Demographic and lifestyle information was obtained by
questionnaire. Smoking status was classified as non-
smoker or current smoker. Women were classified as
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Page 2 of 8nulliparous if they had not had a live birth or parous if
they had had at least one live birth. Physical activity was
assessed as we have described previously [18] by the
International Physical Activity Questionnaire (IPAQ)
and as mean steps per day measured by Yamaz ped-
ometer worn for seven days. The questionnaire asked
whether participants had ever been told by a doctor that
they had polycystic ovaries (PCO) or polycystic ovary
syndrome (PCOS).
Statistical Analysis
The unequal variance t-test was used to assess differ-
ences in normally-distributed continuous characteristics
in this study across categorized menstrual cycle pattern
(regular and irregular), the Wilcoxon rank-sum test was
used for skewed continuous variables and the two-sam-
ple test of proportions was used for dichotomised cov-
ariates. Spearman correlations were used to estimate
crude associations between continuous exposures and
QUS. Multivariable linear regression analysis was used
to explore the association between all QUS measures
and menstrual cycle pattern and hormonal factors (tes-
tosterone, SHBG and FAI). QUS parameters and hormo-
nal factors were logarithmically transformed to fit linear
regression models and standardised to enable direct
comparisons between BUA, SOS and QUI. The coeffi-
cients represent a change of one standard deviation.
Age, BMI and smoking were considered as confounders
or covariates of importance, and adjusted for in multi-
variable models where appropriate. All statistical ana-
lyses were performed on intercooled Stata 9.2 for
windows (Statacorp, Texas, USA).
Results
In this relatively young study sample with age range of
26-36 years (mean age 32 years; mean BMI 24.8 kg/m
2),
most women were married or living as married (61.7%)
and were non-smokers (85.7%). Over half the women
had had at least one livebirth (53.7%). Only 11% of par-
ticipants had irregular menstrual cycles. Very few
women sampled reported having ever been told by a
doctor that they had PCO or PCOS (n = 9 with irregu-
lar cycles, n = 9 with regular cycles). Women currently
taking hormonal medication for PCOS (n = 2) were
ineligible for this analysis and excluded. Compared with
other women in this study, women who were excluded
due to current use of hormonal contraceptives or hor-
monal medications, were slightly younger (30.7 vs 31.5
years) and more likely to have a history of menstrual
irregularity (21.6% vs 10.7%), but there was no signifi-
cant difference in BMI between the groups (25.0 kg/m
2
vs 24.8 kg/m
2, p = 0.54) and similar proportions were
current smokers (13.2% vs 14.3%, p = 0.69).
In the unadjusted analysis, women with irregular
cycles had higher FAI, SOS and QUI, and lower SHBG
compared with those with regular cycles (Table 1). The
difference in bone mass between women with regular
and irregular cycles is illustrated in Figure 1. There were
no significant differences in age, body composition mea-
surements, marital status, number of live births, smok-
ing and plasma insulin levels between women with
irregular cycles and regular cycles. However, all anthro-
pometric measures including BMI, waist circumference
and waist to hip ratio were significantly associated with
BUA (p < 0.05-0.01) (Table 2) as were hormonal factors
with a positive association between testosterone and
FAI, and a negative association with SHBG (all p < 0.01)
(data not shown).
There were significant associations between hormonal
factors and BUA, SOS and QUI measurements found
in both unadjusted correlation analysis (Table 2) and
adjusted analysis (Table 3). Total testosterone and
Table 1 Characteristics of participants by menstrual cycle
pattern
Characteristics Regular cycle
N = 341
Irregular cycle
N=4 1
P
values
Age (year)
a 31.6 (2.6) 30.9 (2.4) 0.11
Anthropometrics
a
Body mass index (kg/m
2) 24.8 (5.0) 24.5 (5.9) 0.77
Waist circumference (cm) 78.8 (11.4) 77.8 (13.3) 0.65
Waist-hip ratio 0.757(0.062) 0.760 (0.061) 0.75
Married
b % 62 56 0.44
Parous
b % 54 49 0.50
Current smoker
b % 15 13 0.73
Physical activity (PA)
c
Pedometer steps (per
day)
8331 (6758-
10623)
8325 (6715-
10992)
0.68
Leisure time PA (min/
week)
120 (0-219) 66 (0-180) 0.24
Total PA (min/week) 680 (385-1030) 560 (300-970) 0.27
Hormonal factors
c
Testosterone (nmol/L) 1.50 (1.22-1.86) 1.53 (1.35-1.89) 0.24
SHBG (nmol/L) 50.3 (35.8-68.0) 43.6 (30.1-54.6) 0.01
Free androgen index 2.94 (2.00-4.47) 4.22 (2.60-6.24) 0.01
Insulin (mU/l) 3.9 (5.3-7.5) 3.5 (4.9-7.9) 0.85
Quantitative
ultrasound
c:
BUA (dB/MHz) 73.6 (65.4-84.6) 78.7 (67.9-87.1) 0.10
SOS (m/s) 1563 (1543-
1587)
1569 (1557-
1606)
0.02
QUI (%) 99.5 (88.6-114.1) 106.7 (94.6-
121.6)
0.03
a presented by mean and standard deviation (SD), P values derived from
unequal variance t-test.
b presented by percentage, P values derived from test of proportions.
c presented by median (inter-quarter range), P values from Wilcoxon rank-sum
test. Bold denotes significant results.
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Page 3 of 8FAI were significantly positively associated with QUS
measurements, while SHBG was negatively associated
with QUS measures. These associations remained signif-
icant after adjustment for confounders with the excep-
tion of SHBG and BUA. Further adjustment for history
of PCO/PCOS did not change the significant
associations. The association between hormonal factors
and QUS measures is further illustrated in Figure 2
where there were dose-response relationships between
BUA measures and hormonal factors, especially for FAI.
The associations between irregular cycles and QUS
measures are presented in Table 4. In multivariable
regression analysis, irregular cycles remained significant
associations with SOS and QUI (b=0 . 3 8f o rb o t h ,p<
0.05), with a consistent trend for BUA (b =0 . 3 1 ,p=
0.06) after adjustment for confounders. The strength of
P=0.10
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Figure 1 Standardized broadband ultrasound attenuation
(BUA), speed of sound (SOS) and quantitative ultrasound index
(QUI) for women with regular and irregular cycles. Error bars
indicate 95% confidence intervals.
Table 2 Spearman correlation coefficients (r) for
associations of quantitative ultrasound measures and
continuous variables in the study
Characteristics BUA SOS QUI
rP rP rP
Anthropometrics
Body mass index 0.17 < 0.01 -0.01 0.79 0.05 0.35
Waist circumference 0.17 < 0.01 -0.01 0.86 0.05 0.32
Waist-hip-ratio 0.14 0.01 0.03 0.57 0.07 0.16
Hormonal factors
Testosterone 0.14 0.01 0.09 0.08 0.11 0.04
SHBG -0.16 < 0.01 -0.14 0.01 -0.16 < 0.01
Free androgen index 0.21 < 0.001 0.16 < 0.01 0.19 < 0.001
SHBG = sex hormone-binding globulin. BUA = broadband ultrasound
attenuation. SOS = speed of sound. QUI = quantitative ultrasound index. Bold
denotes significant association (P < 0.05).
Table 3 Association between quantitative ultrasound
(QUS) parameters and hormonal factors
Unadjusted
model
Adjusted model
(n = 382)
b (95% CI)
Model 1
(n = 358)
b (95% CI)
Model 2
(n = 358)
b (95% CI)
BUA
Testosterone 0.15 (0.04, 0.24) 0.14 (0.04, 0.25) 0.13 (0.03, 0.24)
SHBG -0.14
(-0.24, -0.04)
-0.07 (-0.19, 0.05) -0.05 (-0.17, 0.06)
FAI 0.18 (0.08, 0.28) 0.14 (0.03, 0.26) 0.13 (0.01, 0.24)
SOS
Testosterone 0.11 (0.01, 0.21) 0.13 (0.03, 0.24) 0.12 (0.02, 0.23)
SHBG -0.13
(-0.23, -0.03)
-0.16
(-0.27, -0.04)
-0.14 (-0.26,
-0.02)
FAI 0.16 (0.06, 0.26) 0.20 (0.08, 0.31) 0.18 (0.06, 0.29)
QUI
Testosterone 0.12 (0.02, 0.22) 0.14 (0.03, 0.24) 0.13 (0.02, 0.23)
SHBG -0.14
(-0.24, -0.04)
-0.13
(-0.25, -0.01)
-0.11 (-0.23, 0.01)
FAI 0.17(0.07, 0.27) 0.18 (0.07, 0.29) 0.16 (0.05, 0.28)
BUA = broadband ultrasound attenuation. SOS = speed of sound. QUI =
quantitative ultrasound index. SHBG = sex hormone-binding globulin. FAI =
free androgen index. QUS measures and hormonal parameters were log
transformed before converted into standardized variables. b = standardised
beta coefficients. Model 1 adjusted for age, BMI and smoking. Model 2
further adjusted for menstrual cycle pattern. Bold denotes significant
association (P < 0.05).
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adjusted for hormonal factors (testosterone, SHBG and
FAI separately), with maximally a 27% decrease in the
coefficient when further adjusted for FAI, and a lesser
effect when adjusted for total levels of testosterone.
However women with irregular cycles still had an
increase of 0.30-0.31 in the standardized log-trans-
formed SOS and QUI and this corresponds to a maxi-
mum 6% increase in the mean QUS measurements. We
recalculated free testosterone (FT) in the equation by
taking into account the laws of mass action and using a
stable mean of albumin concentration (assumed to be
43 g/l), and found that the associations between men-
strual irregularity and bone mass were nearly the same
when adjusted for FAI and FT. Further adjustment for a
history of ever been told by a doctor that they had PCO
or PCOS made the associations a little stronger. When
irregular and very irregular cycles were examined sepa-
rately, the adjusted associations were similar in magni-
tude but were not statistically significant, likely due to
lower power (n = 22 for irregular, n = 19 for very irre-
gular; data not shown).
Discussion
In this cross-sectional study of a population-based sam-
ple of premenopausal women (37% overweight or
obese), an irregular menstrual cycle was associated with
higher quantitative ultrasound measurements including
BUA, SOS and QUI. This association was independent
of age and BMI but was moderately reduced when
further adjusted for hormonal factors, particularly for
SHBG and FAI, suggesting that these hormonal factors
partially mediate the associations.
Studies have reported a negative association between
oligo/amenorrhea and bone mineral density [8-11,19] in
female athletes with low BMI. The bone loss was attrib-
uted to low levels of estrogen and/or chronic energy
deficiency caused by restricted food intake and extensive
training [20]. However, these conditions are not com-
mon in the general community and these results may
not be applicable to young women affected by today’s
obesity epidemic. In fact, in this population-based sam-
ple of young women, the mean BMI was 24.8 kg/m
2
which is close to the lower cut-point of overweight (25-
30 kg/m
2) based on the WHO categorization [21]. We
found that irregular cycles were associated with higher
bone mass and this was partially mediated by SHBG
and FAI. This is consistent with other studies’ findings
that bone mass was associated with higher levels of
androgens and lower levels of SHBG [22-24]. Further-
more we found a significant dose-response relationship
between hormonal factors and bone mass, especially
for FAI.
Few studies have examined bone mass and the asso-
ciation with menstrual irregularity and androgens in
population-based samples of premenopausal women
though positive associations between amenorrhea and
bone mass were reported in women with hirsutism and
PCOS - conditions with excess androgen. Endogenous
P(trend)<0.05
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Figure 2 Standardized broadband ultrasound attenuation
(BUA) across quartiles of testosterone, sex hormone-binding
globulin (SHBG) and free androgen index (FAI). Error bars
indicate 95% confidence intervals. Hormonal factors were
standardized parameters.
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Page 5 of 8androgens were associated with menstrual irregularity in
population-based [12,13] and clinical samples [25], and
bone mass in premenopausal women [22,23,26], but
these associations were investigated separately. An
important strength of our study, therefore, was its popu-
lation-based sample and ability to examine the role of
hormonal factors.
The mechanism for the association between menstrual
irregularity, hormonal factors and bone mass is not
clear. However the association between menstrual irre-
gularity and bone mass had a moderate reduction in
s t r e n g t ha n dl o s ts i g n i f i c a n c e when further adjusted for
either SHBG or FAI separately. This suggests that bone
mass could be influenced by SHBG through the regula-
tion of free testosterone levels. Our result is consistent
with a prospective study which examined 231 women
aged 32-77 years over 2-8 years period and found, in
addition to age and weight, SHBG was a strong inde-
pendent predictor of BMD[26]. A recent editorial dis-
cussed a potential dual role for SHBG (inhibitor or
facilitator) in regulating sex hormone action [27] follow-
ing a genetic study of polymorphisms in the SHBG gene
promoter which found that serum levels of SHBG were
positively associated with BMD in elderly men [28].
However our result favours the free hormone hypothesis
that SHBG inhibits sex hormone bioavailability, rather
than augments sex hormone action.
There were several limitations which should be con-
sidered when interpreting these findings. First, men-
strual cycle characteristics were obtained by self-
administered questionnaire which did not include speci-
fic criteria for women to assess their cycle regularity.
This may have resulted in misclassification. However, it
is unlikely that this error would be differential with
respect to bone mass or hormonal factors since both
QUS and hormonal factors were measured at the same
time that women reported their menstrual cycles.
Therefore the association between irregular cycles and
bone mass may be underestimated in our study. Second,
we did not have dual-energy x-ray absorptiometry
(DXA) measurement of BMD; however QUS results cor-
relate well with BMD measured by DXA at the heel [29]
and predict fracture risk similarly to DXA [30]. This
study was conducted in community centres across Aus-
tralia so DXA measurements were not feasible. Further-
more, use of a portable QUS machine avoided
standardisation issues which could have been a major
problem had we used multiple DXA instruments at dif-
ferent sites. Third, we did not assess endogenous estro-
gens which show substantial variation during the
menstrual cycle. Clearly, es t r o g e n sp l a yam a j o rr o l ei n
regulating bone mass in both males and females. Pre-
vious studies examining both estrogens and androgens
in premenopausal women found that androgen but not
estrogen was associated with bone mass [22,26] suggest-
ing premenopausal estrogen levels may be sufficient in
most women. Due to logistic issues, the blood sample
collection was not timed with the menstrual cycle possi-
bly introducing some measurement error as testosterone
varies with the menstrual cycle [31]. Another limitation
is that some young women with irregular cycles may
have had undiagnosed PCOS. However, this sample of
young women had testosterone levels typically within the
normal range. Exclusion of eight women who had testos-
terone levels higher than 2.9 nmol/l (the upper limit of
the laboratory’s reference range for premenopausal
women with normal menstrual cycles and no evidence of
polycystic ovaries on ultrasound) or 24 women who had
SHBG levels less than 24 nmol/l (the lowest levels for fol-
licular phase for premenopausal women) made little dif-
ference to the findings. In addition, adjustment for a
h i s t o r yo fe v e rb e i n gt o l db yad o c t o rt h e yh a dP C Oo r
Table 4 Association between quantitative ultrasound (QUS) measures and menstrual irregularity adjusted by each
hormonal factor separately
Adjusted model *
b (95% CI)
Adjusted model
+ testosterone
b (95% CI)
Adjusted model
+ SHBG
b (95% CI)
Adjusted model
+FAI
b (95% CI)
BUA
Regular cycle Ref Ref Ref Ref
Irregular cycle 0.31 (-0.01, 0.64) 0.29 (-0.04, 0.61) 0.28 (-0.05, 0.61) 0.25 (-0.07, 0.58)
SOS
Regular cycle Ref Ref Ref Ref
Irregular cycle 0.38 (0.05, 0.71) 0.36 (0.03, 0.68) 0.31 (-0.02, 0.64) 0.30 (-0.03, 0.63)
QUI
Regular cycle Ref Ref Ref Ref
Irregular cycle 0.38 (0.05, 0.71) 0.36 (0.03, 0.68) 0.32 (-0.01, 0.65) 0.31 (-0.02, 0.63)
BUA = broadband ultrasound attenuation. SOS = speed of sound. QUI = quantitative ultrasound index. SHBG = sex hormone-binding globulin. FAI = free
androgen index. QUS measures were log transformed before converted into standardized values. b = standardised beta coefficients. *Adjusted model controlled
for age and BMI. Bolder denotes significant association (P < 0.05).
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Page 6 of 8PCOS did not decrease the associations. Further, the
relatively low percentage of eligible participants with
complete data may limit the generalizability of our find-
ings to the general population. Finally, we cannot be cer-
tain of the causal direction of the associations observed
due to the cross-sectional design of this study. Thus, a
longitudinal study is necessary to confirm these findings.
Conclusions
Irregular menstrual cycles were associated with higher
bone mass in this population-based sample of premeno-
pausal women suggesting menstrual disturbance should
continue to be evaluated but may be less harmful for
bone mass than previously believed. The association
between menstrual irregularity and bone mass was par-
tially mediated by markers of androgen status especially
free testosterone.
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